Biofabrication Plastics Market to surpass USD 34.8 billion in 2030, at a CAGR of 7.3%

Biofabrication Market was at USD 21.0 billion in 2023-e and projected to grow at a CAGR of 7.3% through 2030 to reach USD 34.8 billion. Bioinks serve as the "ink" in bioprinting processes, containing living cells and supporting materials. Hydrogels, often used as bioinks, are three-dimensional networks of hydrophilic polymers that mimic the extracellular matrix. Innovations in hydrogel formulations, such as natural polymers (like collagen and alginate) or synthetic polymers, contribute to the creation of bioinks with varying mechanical properties suitable for different tissues.

Scaffolds provide structural support for tissue growth and help guide the formation of complex structures. These materials need to be biocompatible, provide mechanical stability, and degrade at a controlled rate as the tissue matures. Combining different biomaterials to form composite materials allows researchers to leverage the strengths of individual components. For example, a composite bioink or scaffold integrates natural polymers with nanomaterials to enhance mechanical strength or conductivity.

Source: Intent Market Research Analysis

Biofabrication techniques are employed to create microscale devices known as "organs-on-a-chip." For example, lung-on-a-chip or liver-on-a-chip models can be used to investigate respiratory diseases or liver disorders. Biofabrication enables the creation of three-dimensional tumor models that closely resemble the in vivo tumor microenvironment. These models are valuable for studying cancer progression, drug responses, and interactions between cancer cells and surrounding tissues. With the ability to use patient-derived cells, biofabrication allows for the creation of patient-specific disease models. This is particularly relevant in precision medicine, where researchers can study how a particular disease manifests in an individual patient's cells.

Microfabrication techniques play a crucial role in biofabrication, enabling the precise construction of intricate structures at the microscale level. Microscale 3D printing techniques, such as two-photon polymerization and laser-assisted printing, enable the fabrication of complex structures with high resolution at the microscale. These techniques are valuable for creating intricate tissue scaffolds and microfluidic devices. Bioprinting at the microscale involves the precise deposition of biomaterials and cells to create microscale tissue constructs. This is essential for replicating the cellular organization found in native tissues. In biofabrication, microarrays are employed for screening multiple factors simultaneously to optimize cell culture conditions and study cellular responses.

Several prominent research institutions and universities in Europe are at the forefront of biofabrication research. These institutions often collaborate with industry partners to advance the field. Examples include the University of Maastricht in the Netherlands, the University of Würzburg in Germany, and the University of Manchester in the United Kingdom. he regulatory landscape in Europe influences the development and adoption of biofabrication technologies. Compliance with European Medicines Agency (EMA) regulations and other relevant standards is crucial for the translation of biofabricated products into clinical applications.

The major players operating in the market are Prominent players include Allevi, Cellink Global, Cyfuse Biomedical, Danaher, Envisiontec, Eppendorf, Inventia Life Science, Merck, Organovo Holdings, Poietis, Regemat 3D, Sartorius Stedim Biotech, Thermo Fisher Scientific, Vivax Bio and 3D Bioprinting Solutions.